Diffusion-weighted MR imaging for the regional characterization of liver tumors

Radiology

Volumn 264, Issue 2, 2012, Pages 464-472

  Wagner, Mathilde ^a   Doblas, Sabrina ^a   Daire, Jean Luc ^a   Paradis, Valérie ^a   Haddad, Nathalie ^a   Leitão, Helena ^b   Garteiser, Philippe ^a   Vilgrain, Valérie ^a   Sinkus, Ralph ^a   Van Beers, Bernard E ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

GADOTERATE MEGLUMINE;

ADULT; AGED; APPARENT DIFFUSION COEFFICIENT; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; FEMALE; FIBROSIS; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; KRUSKAL WALLIS TEST; LIVER CANCER; LIVER RESECTION; MALE; PERFUSION RELATED DIFFUSION COEFFICIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PURE DIFFUSION COEFFICIENT; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING; TUMOR FIBROSIS; TUMOR NECROSIS;

ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MEGLUMINE; MIDDLE AGED; NECROSIS; ORGANOMETALLIC COMPOUNDS; PROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 84864355948     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12111530     Document Type: Article

References (32)

1. Goldberg SN, Gazelle GS, Compton CC, Mueller PR, Tanabe KK. Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer 2000;88(11):2452-2463. (Pubitemid 30331950)
2. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35(3): 421-430. (Pubitemid 32844200)
3. Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005;42(5):1208-1236. (Pubitemid 43112690)
4. Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007;18(2):299-304. (Pubitemid 46323097)
5. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100(10):698-711.
6. Blazer DG 3rd, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008;26(33):5344-5351.
7. Rimola J, Forner A, Reig M, et al. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 2009;50(3):791-798.
8. Kim T, Hori M, Onishi H. Liver masses with central or eccentric scar. Semin Ultrasound CT MR 2009;30(5):418-425.
9. Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009;302(21):2338-2344.
10. Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol 2009;193(4):1044-1052.
11. Hwang J, Kim SH, Kim YS, et al. Gadoxetic acid-enhanced MRI versus multiphase multidetector row computed tomography for evaluating the viable tumor of hepatocellular carcinomas treated with image-guided tumor therapy. J Magn Reson Imaging 2010;32(3):629-638.
12. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30(1): 52-60.
13. Kim SA, Lee JM, Lee KB, et al. Intrahepatic mass-forming cholangiocarcinomas: enhancement patterns at multiphasic CT, with special emphasis on arterial enhancement pattern-correlation with clinicopathologic findings. Radiology 2011;260(1):148-157.
14. Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. Radiology 2010;254(1): 47-66.
15. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 2009;250(2): 466-473.
16. Thoeny HC, De Keyzer F, Chen F, et al. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology 2005;234(3):756-764. (Pubitemid 40250819)
17. Woodhams R, Kakita S, Hata H, et al. Diffusion-weighted imaging of mucinous carcinoma of the breast: evaluation of apparent diffusion coefficient and signal intensity in correlation with histologic findings. AJR Am J Roentgenol 2009;193(1):260-266.
18. Bruegel M, Holzapfel K, Gaa J, et al. Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echoplanar MR imaging technique. Eur Radiol 2008;18(3):477-485. (Pubitemid 351248179)
19. Parikh T, Drew SJ, Lee VS, et al. Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology 2008;246(3):812-822.
20. Taouli B, Vilgrain V, Dumont E, Daire JL, Fan B, Menu Y. Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology 2003;226(1):71-78. (Pubitemid 36163910)
21. Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 1988;168(2):497-505.
22. Lewin M, Fartoux L, Vignaud A, Arrivé L, Menu Y, Rosmorduc O. The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. Eur Radiol 2011;21(2):281-290.
23. Yamada I, Aung W, Himeno Y, Nakagawa T, Shibuya H. Diffusion coefficients in abdominal organs and hepatic lesions: evaluation with intravoxel incoherent motion echo-planar MR imaging. Radiology 1999;210(3):617-623. (Pubitemid 29124018)
24. Ho VB, Allen SF, Hood MN, Choyke PL. Renal masses: quantitative assessment of enhancement with dynamic MR imaging. Radiology 2002;224(3):695-700. (Pubitemid 34919800)
25. Kim SY, Lee SS, Byun JH, et al. Malignant hepatic tumors: short-term reproducibility reproducibility of apparent diffusion coefficients with breath-hold and respiratory-triggered diffusion-weighted MR imaging. Radiology 2010;255(3):815-823.
26. Doblas S, Wagner M, Daire JL, et al. Reproducibility of perfusion and pure diffusion parameters in multi-b diffusion-weighted MR imaging of liver tumors [abstr]. In: Proceedings of the Nineteenth Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2011; 6755.
27. Gabata T, Matsui O, Kadoya M, et al. Delayed MR imaging of the liver: correlation of delayed enhancement of hepatic tumors and pathologic appearance. Abdom Imaging 1998;23(3):309-313. (Pubitemid 28213309)
28. Maetani Y, Itoh K, Watanabe C, et al. MR imaging of intrahepatic cholangiocarcinoma with pathologic correlation. AJR Am J Roentgenol 2001;176(6):1499-1507. (Pubitemid 32510270)
29. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25(13):1753-1759. (Pubitemid 46797957)
30. Luciani A, Vignaud A, Cavet M, et al. Liver cirrhosis: intravoxel incoherent motion MR imaging - pilot study. Radiology 2008;249(3):891-899.
31. Nasu K, Kuroki Y, Nawano S, et al. Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology 2006;239(1):122-130.
32. Kwee TC, Takahara T, Koh DM, Nievelstein RA, Luijten PR. Comparison and reproducibility of ADC measurements in breathhold, respiratory triggered, and free-breathing diffusion-weighted MR imaging of the liver. J Magn Reson Imaging 2008;28(5):1141-1148.